← All trials
NCT04459715
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 7, 2020
- Primary completion
- Dec 1, 2024
- Completion date
- Apr 30, 2027
- First posted
- Jul 7, 2020
- Last posted
- Dec 31, 2020
- Enrollment
- 700
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- DebiopharmLead sponsor
- GORTEC (Head and Neck Oncology and Radiotherapy Group)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.